Sanjay Chandru Keswani
Known title: Chief Medical OfficerCIK: 0001818524
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
ANNX Listed Among Health Care Stocks Moving Pre-Market. Annexon Inc. was included in a list of health care stocks showing movement during Friday's pre-market session. The stock is currently trading near its 52-week low, with technical signals indicating a breakdown below the Bollinger Bands. Analysts maintain a wide range of price targets, reflecting uncertainty about the company's future performance.
Transaction History
| NBIX | ▼ Sell | Tax Withholding | 2,112 | $330K | 9/11/2026 | View on chart |
| NBIX | ▲ Buy | Grant | 3,914 | $0 | 9/11/2026 | View on chart |
| NBIX | ▼ Sell | Tax Withholding | 1,733 | $268K | 6/2/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 3,212 | $0 | 6/2/2026 | View on chart |
| ANNX | ▲ Buy | Grant | 12,500 | $0 | 2/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation
Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.